Introduction
The previous article in this series covered psilocybin's metabolic pathway, the enzymes that convert it to psilocin and break psilocin down further. This article covers the complementary question: not what happens to the molecule chemically, but how it moves through the body over time. Pharmacokinetics, absorption, distribution, metabolism, and excretion, often abbreviated ADME, is the framework clinical researchers use to describe exactly that movement, and it's the foundation for how psilocybin dosing, timing, and trial design decisions actually get made.
This article works through each ADME component in turn, drawing on a substantial and increasingly consistent body of clinical pharmacokinetic data published over the past several years, including a comprehensive 2025 systematic review that pooled raw data across twelve independent clinical datasets.
As with the rest of this series, this is a pharmacology explainer intended for scientific and educational purposes. It does not provide dosing guidance.
Absorption: How Quickly Does Psilocybin Reach the Bloodstream?
Following oral administration, the near-universal route used in modern clinical research, psilocybin is absorbed and converted to psilocin quickly. Across included studies in recent systematic reviews, time to maximum plasma concentration (Tmax) for unconjugated psilocin has ranged from roughly 1.8 to 4 hours, with individual fixed-dose clinical trials reporting mean Tmax values clustering tightly around 2 hours, 2.0, 1.9, and 2.2 hours for 15 mg, 25 mg, and 30 mg psilocybin doses respectively in one well-controlled study. Some earlier pharmacological reviews report psilocin becoming detectable in plasma within as little as 20 to 40 minutes of an oral dose taken on an empty stomach, with full peak concentrations typically reached somewhat later, in the range of 80 to 120 minutes depending on the specific study and dosing conditions.
An important structural detail about absorption: intact psilocybin itself is essentially undetectable in plasma following oral dosing, even in studies designed specifically to look for it. In one comparative pharmacokinetic study using intravenous versus oral administration in an animal model, psilocybin was detectable in the bloodstream only when given intravenously; when given orally, it was not detectable at any tested dose, a finding attributed to its rapid conversion to psilocin during and immediately after absorption. This is consistent with everything covered in the earlier articles in this series: for practical pharmacokinetic purposes, oral psilocybin functions as a delivery system for psilocin rather than as a circulating compound in its own right.
Bioavailability: How Much of the Dose Actually Reaches Circulation?
Bioavailability, the fraction of an administered dose that reaches systemic circulation in active form, has been a comparatively under-studied parameter for psilocybin, largely because establishing absolute bioavailability requires a direct intravenous comparison arm, and the vast majority of clinical psilocybin research to date has used oral dosing exclusively. Where bioavailability has been measured, reported figures cluster in a broadly similar range: one clinical pharmacokinetic study reported psilocin bioavailability of approximately 52.7% (±20%) following a weight-based oral dose, while a separate, larger systematic review estimated bioavailability at approximately 55% based on one dataset with both oral and intravenous data available. Older pharmacological reviews describe a comparable figure, characterizing psilocybin's oral bioavailability as being in the neighborhood of 50%, meaning roughly half of an ingested dose is available to exert pharmacological effect after first-pass metabolism and absorption losses are accounted for.
The relatively wide confidence interval around these bioavailability estimates (±20% in the case above) reflects genuine inter-individual variability rather than simply measurement noise, a pattern consistent with what would be expected given the CYP2D6 genetic polymorphism and other metabolic variability discussed in the Psilocybin Metabolism article. A recent systematic review explicitly flagged this as an area needing further research, noting that information on absolute bioavailability remains limited and identifying it, along with food effects, as a priority for future clinical pharmacokinetic studies.
Distribution: Where Does Psilocin Go in the Body?
Once absorbed, psilocin distributes extensively throughout body tissues rather than remaining confined to the bloodstream. Reported values for apparent volume of distribution are large, ranging from roughly 277 to 1016 liters in one systematic review, and 505 to 1267 liters in another, independent pooled analysis, figures that vastly exceed total body water or blood volume and indicate that psilocin readily crosses into and accumulates within tissue compartments outside the vascular system, consistent with its need to cross the blood-brain barrier to reach its receptor targets in the central nervous system.
This extensive distribution also produces the biphasic plasma concentration-time profile reported in several pharmacokinetic studies: an initial, faster distribution phase as the compound moves from blood into tissue, followed by a slower terminal elimination phase as it's cleared from the body. Modeling work distinguishing these two phases has reported a distribution half-life on the order of roughly 2 hours in animal models, distinct from, and shorter than, the terminal elimination half-life discussed below.
Body weight, notably, does not appear to meaningfully influence how much psilocin reaches circulation. Pharmacokinetic analysis has found that body weight had no significant effect on either the area under the concentration-time curve or peak plasma concentration of psilocin, a finding that lends pharmacokinetic support to the increasingly common clinical trial practice of using fixed-dose regimens (for example, a standard 25 mg dose) rather than weight-adjusted dosing. Post-hoc comparisons between weight-based and fixed-dosing approaches have similarly found no significant difference in subjective response between the two strategies, reinforcing fixed dosing as the more practical and equally effective approach for most clinical trial purposes.
Elimination: How Long Does Psilocin Stay in the Body?
Psilocin is eliminated according to first-order kinetics, meaning a constant proportion of the remaining drug is cleared per unit time rather than a fixed absolute amount, the standard elimination pattern for most small-molecule drugs. Reported terminal elimination half-lives cluster in a moderately consistent range across the literature: a large pooled systematic review reports a range of 1.23 to 4.72 hours across included clinical datasets, while individual fixed-dose studies and earlier pharmacological reviews more commonly cite a narrower range of roughly 2 to 3 hours.
Urinary excretion data adds useful granularity to this picture. Only a small fraction of an administered psilocybin dose, commonly reported in the range of 1.5% to 3.4%, is ultimately excreted as free, unconjugated psilocin in urine, a figure consistent across multiple independent studies. The clear implication, reinforcing what was covered in the metabolism article, is that the overwhelming majority of a psilocybin dose is eliminated not as intact psilocin but as its downstream metabolites, primarily 4-hydroxyindole-3-acetic acid, along with a smaller contribution from conjugated psilocin glucuronide. Notably, some conversion to 4-hydroxyindole-3-acetic acid appears to occur even before systemic psilocin absorption is complete, suggesting first-pass metabolic processing begins essentially in parallel with absorption rather than strictly afterward.
Renal excretion has been consistently identified as the dominant elimination pathway across the human clinical studies that have specifically examined this question, with fecal elimination playing a comparatively minor role.
Dose Linearity: Does a Higher Dose Produce Proportionally More Exposure?
One of the more clinically useful findings in recent psilocybin pharmacokinetic research is that, within the dose range most commonly used in clinical trials, psilocin's pharmacokinetics appear to be dose-proportional, meaning plasma concentrations of psilocin and its metabolites increase in a fairly linear, predictable fashion as the administered psilocybin dose increases. This dose-proportionality has been reported specifically across an oral dose range of roughly 0.3 to 0.6 mg/kg, which covers the great majority of doses used in contemporary clinical research; a commonly used 25 mg fixed dose corresponds to approximately 0.3 mg/kg for an average-weight adult, while 35 mg is generally considered a higher-end research dose.
This dose-linearity finding is worth distinguishing carefully from the non-linear, dose-dependent patterns discussed in the Psilocybin Pharmacology article regarding certain downstream biological effects, such as the inverted dose-response relationship observed for hippocampal neurogenesis in animal models, or the bimodal 5-HT2C-mediated behavioral response. Plasma pharmacokinetics being linear does not imply that every biological or behavioral effect downstream of that exposure will scale linearly in turn. A drug's concentration in the blood and the intensity or nature of its ultimate physiological effect are governed by two different sets of relationships, the pharmacokinetic relationship between dose and concentration, and the pharmacodynamic relationship between concentration and effect, and confusing the two is a common source of error in less careful secondary reporting on this subject.
Some older pharmacological reviews add useful threshold-level context to this picture, describing psychological effects as generally emerging once plasma psilocin levels reach a threshold in the range of roughly 4–6 micrograms per milliliter, with a subjectively detectable but sub-threshold effect sometimes reported at oral doses as low as 3–5 mg, and fuller psychotropic effects more commonly associated with doses in the 8–25 mg range, though considerable inter-individual variability is consistently emphasized across this literature. This threshold-based framing is a useful complement to the dose-linearity finding above: even though plasma concentration rises in a predictable, roughly proportional way with dose, the point at which that rising concentration crosses into a subjectively noticeable or clinically meaningful range can still vary meaningfully from person to person, which is part of why individual pharmacokinetic variability remains a live topic in dosing research even within a framework of overall dose-proportionality.
Route of Administration: Why Oral Dosing Dominates Clinical Research
Nearly all modern clinical psilocybin research uses oral administration, and this is reflected clearly in the pharmacokinetic literature: of the clinical datasets pooled in one major 2025 systematic review, only a single study investigated intravenous psilocybin, with every other included dataset using oral dosing. This near-universal preference for oral administration reflects practical clinical trial considerations, ease of administration, consistency with how the compound would likely be used in any eventual approved therapeutic context, and the substantial existing body of safety and dosing data built specifically around oral protocols, rather than any pharmacokinetic superiority of the oral route itself.
Comparative pharmacokinetic modeling between intravenous and oral administration has highlighted an important methodological caveat worth flagging for anyone interpreting cross-route pharmacokinetic models: physiologically based pharmacokinetic simulations comparing the two routes have shown a tendency toward under-prediction of concentrations for oral administration and over-prediction for intravenous administration relative to observed data, indicating that current PBPK models, while broadly useful, still have room for refinement in fully capturing route-specific absorption and first-pass effects.
This route-of-administration question also connects back to the analytical detectability discussion raised earlier in this article. Because intact psilocybin is essentially undetectable following oral dosing but becomes measurable when administered intravenously, the intravenous route has proven specifically useful for research purposes that require observing psilocybin itself, rather than only its metabolite psilocin, for example, establishing absolute bioavailability figures, which mathematically require comparing oral and intravenous exposure to the same compound directly. This is precisely why the handful of intravenous psilocybin pharmacokinetic studies that do exist, despite their small number relative to oral studies, carry disproportionate scientific value: they fill a specific methodological gap that oral-only study designs cannot address on their own, regardless of how many additional oral studies are conducted.
Open Questions: Food Effects and Remaining Gaps
Despite the substantial and increasingly consistent pharmacokinetic dataset now available for psilocybin, some genuinely basic questions remain incompletely answered. A major systematic review covering data across four studies with known fasting status found no reported food effects, meaning no clear evidence, in the available data, that taking psilocybin with versus without food meaningfully alters its absorption or plasma exposure. However, the same review was explicit that this is a data-availability limitation rather than a settled negative finding, and it specifically named the effect of food, along with absolute bioavailability more broadly, as priorities for future clinical pharmacokinetic research. This is a useful reminder that "no effect found" and "no effect exists" are not the same claim, particularly in a research area where the number of well-controlled human studies, while growing, is still modest by the standards of more extensively studied drug classes.
This gap is worth taking seriously rather than treating as a minor footnote, because food effects are a routine and often clinically significant consideration for orally administered drugs generally, altering gastric emptying rate, gut pH, or interacting with first-pass metabolic enzymes in ways that can meaningfully shift a drug's absorption profile. For a compound whose absorption depends specifically on rapid intestinal dephosphorylation via alkaline phosphatase, and whose bioavailability already shows considerable inter-individual variability even under controlled fasting conditions, it would not be surprising if food intake turned out to influence either the rate or extent of psilocin absorption once specifically studied with an adequately powered trial design. Until that dedicated research is conducted, however, the honest and accurate position is that the question remains open rather than resolved in either direction.
Frequently Asked Questions
How long does it take for psilocybin to reach peak concentration in the blood? Time to maximum plasma concentration (Tmax) for psilocin, psilocybin's active metabolite, typically falls between about 1.8 and 4 hours after oral dosing, with most fixed-dose clinical studies reporting a mean Tmax close to 2 hours.
What is psilocybin's bioavailability? Reported oral bioavailability of psilocin (from psilocybin) is roughly 50–55% based on available studies, though this figure carries a wide confidence interval and remains an area flagged for further research.
How long does psilocin stay in the body? Terminal elimination half-life estimates for psilocin range from roughly 1.2 to nearly 5 hours across pooled clinical data, with most individual studies reporting a half-life in the 2–3 hour range.
Is psilocybin's pharmacokinetics dose-proportional? Yes, within the commonly studied oral dose range of approximately 0.3–0.6 mg/kg, psilocin plasma exposure increases in a roughly linear, dose-proportional manner.
Does body weight affect how much psilocybin someone absorbs? Pharmacokinetic studies have found no significant effect of body weight on psilocin's peak concentration or overall plasma exposure, which supports the common clinical trial practice of using fixed doses rather than weight-adjusted dosing.
Why do almost all psilocybin studies use oral dosing instead of injection? Oral administration matches how psilocybin would likely be used in any future approved therapeutic setting and has the most established safety and dosing precedent. Only a small number of research studies have used intravenous administration, primarily for comparative pharmacokinetic modeling purposes.
Key Takeaways
- Oral psilocybin is absorbed and converted to psilocin quickly, with peak plasma psilocin concentrations typically reached within about 2 hours.
- Reported oral bioavailability of psilocin is approximately 50–55%, though this remains an area with limited data and identified as a research priority.
- Psilocin distributes extensively into body tissue, with a large apparent volume of distribution and a biphasic plasma concentration profile.
- Terminal elimination half-life is typically reported in the 2–3 hour range, though pooled data shows a wider range of roughly 1.2 to nearly 5 hours across studies.
- Only a small fraction of an administered dose (roughly 1.5–3.4%) is excreted as unchanged psilocin; the majority is eliminated via metabolites, primarily 4-HIAA.
- Within the standard clinical dosing range, psilocin pharmacokinetics are dose-proportional, but this pharmacokinetic linearity should not be assumed to extend to every downstream pharmacodynamic effect.
- Body weight does not meaningfully affect psilocin exposure, supporting fixed-dose clinical trial protocols over weight-adjusted dosing.
- Food effects and absolute bioavailability remain incompletely characterized and are flagged as priorities for future research.
This article is for scientific and educational purposes only. It does not provide guidance on acquisition, dosing, or use of psilocybin, and is not a substitute for professional medical or legal advice.